Navigation Links
Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
Date:11/12/2007

PARIS, November 12 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY) has renewed its license to Aureus' AurSCOPE GPCR, and has also licensed Aureus' AurSCOPE Kinase and Ion Channel Knowledge databases.

Aureus Pharma's target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall pharmacological space associated with a target/ligand, researchers can better design and prioritize experiments.

"We are very pleased that Bristol-Myers Squibb has chosen Aureus Pharma as a partner for knowledge based drug discovery," commented Jason Theodosiou, CEO of Aureus Pharma. "Bristol-Myers Squibb has been an important customer since 2002 and we regard their renewal and license extension as confirmation that our knowledge database solutions are meeting the needs of the world's leading pharmaceutical companies."

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus accelerates drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharma topics including ADME/Drug-Drug Interactions and the hERG Channel. The data contained in the Aureus Pharma system is of importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus helps researchers turn data into discovery visit http://www.aureus-pharma.com

Media Contact:

For Aureus Pharma:

Mary E. Donlan, Ph.D

Director of Sales & Marketing

+33-1-40-18-57-59/+33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 The ... at a CAGR of around 7.5% over the ... 2025. Some of the prominent trends that the ... incidences of diseases & graft transplant surgeries and ... Material the market is categorized into immunomodulatory biomaterials, ...
(Date:1/17/2017)... --  Pulmatrix, Inc . (NASDAQ: PULM ), ... to address serious pulmonary diseases, today announced that its ... of CF patients, PUR1900, has been designated as a ... & Drug Administration. Under the QIDP ... of novel drugs against important pathogens, Pulmatrix will receive ...
(Date:1/17/2017)... N.Y. , Jan. 17, 2017  Northwell ... speed the advance of precision cancer research. ... largest health care provider, Northwell Health ... year. Indivumed, GmbH is a Germany ... anti-cancer medical therapies. Together they will greatly expand ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, ... provider of learning and performance management systems for high-consequence industries, announced today that ... “In the life sciences industry, organizations must pay much more attention to the ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... VIEW, Calif. , Dec. 20, 2016  As part ... levels, 23andMe, the leading personal genetics company, recently released its ... Me . The book focuses on the topics of ... Next Generation Science Standards (NGSS) taught in elementary school classrooms ... second in a series by illustrator Ariana Killoran , ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):